Please assess the completion status of the following clinical trial:

Trial Title: Study of Eszopiclone Compared to Placebo in the Treatment of Insomnia Secondary to Perimenopause/Menopause

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Subject must understand the purpose of the study and be willing to adhere to the study schedule and procedures described in this protocol.~* Subject must be between the ages of 40 and 60 years, inclusive, on the day of signing consent.~* Subject must have perimenopausal or menopausal signs and symptoms.~* Subject must report SL of \>45 minutes and \<6 hours of TST at least three times a week over the previous month and symptoms of insomnia must post date onset of perimenopausal or menopausal symptoms.~* Subject's physical exam must show no clinically significant abnormal findings (other than insomnia and menopause symptoms) at screening.~Exclusion Criteria~* Subject has history of circadian rhythm disorder, or travels across \>3 time zones on a regular basis.~* Female subject is pregnant, lactating or within 6-months post partum.~* Subject has a history of drug or alcohol abuse or dependence in the past 2 years or positive urine drug test at screening .~* Subject has unstable medical abnormality, or unstable chronic disease; or history of significant cardiac, renal, or hepatic disease, seizure disorder, or current or past acute suicidal tendencies.~* Subject has participated in any investigational drug study within 30 days prior to screening or plans to participate in another investigational drug study during participation in this study.~* Subject is taking hormone replacement therapy or an hormonal contraceptive, and has not been on a stable dose for a minimum of 60 days prior to study start.~* Subject is known to be seropositive for HIV.~* Subject has a disorder or history of a condition (e.g., malabsorption, gastrointestinal surgery) that may interfere with drug absorption distribution, metabolism, or excretion.~* Subject has a history of malignancy within 5 years, or current malignancy, except for non-melanoma skin cancer.~* Subject has a diagnosis of any psychiatric disorder as identified by a psychiatric screening questionnaire.~* Subject has any primary diagnosis (personality disorder or mental retardation) that would impact the investigator's ability to evaluate the safety or efficacy of the study medication.~* Subject has difficulties in sleep initiation or maintenance associated with other known primary sleep disorders \[e.g. sleep apnea, restless leg syndrome (RLS), or periodic leg movement syndrome (PLMS)\], or has any condition that may affect sleep (e.g., chronic pain, urinary incontinence, etc.).~* Subject has used any drugs known or suspected to affect hepatic or renal clearance capacity within a period of 30 days prior to screening.~* Subject reports consumption of more than two alcoholic beverages daily, 14 or more alcoholic beverages weekly, or five or more alcoholic beverages on any given day.~* Subject is a rotating or third/night shift worker.~* Subject is a staff member or relative of a staff member.~* Subject is experiencing symptoms of premature menopause or surgical menopause.~* Subject has discontinued hormone replacement therapy or a hormonal contraceptive, and has not been off treatment for a minimum of 60 days prior to study start.~* Subject has been on hormone replacement therapy or hormonal contraceptives for greater then one year.

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): eszopiclone 3 mg
- 2 (Type: PLACEBO_COMPARATOR): Placebo tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).